TICKERNERD
Menu
PCSAPCSAHealthcare · Biotechnology

PCSA Stock Forecast: Processa Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 15 Sept 2026
$1.96
+4.08% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 21 of 100 as at 14 Sept 2026 — in the weakest quartile.

Market cap
$5.3M
Ticker Nerd rank
21 / 100
Median analyst target
—
Analysts covering
1
Revenue$0.0
Operating income−$2.3M
Net income−$3.3M
Free cash flow−$2.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.4%
1M
−19.5%
YTD
−32.1%
1Y
−60.9%
From 52W high
−83.7%
From 52W low
+5.8%
$2
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PCSA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Processa Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Sept 2026
21 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
96
Growth
62
Accruals
61
Issuance
39
Volatility
35
Revisions
25
Value
18
Quality
13
Momentum
7

Size (96): Smaller than most of the companies we track.

Momentum (7): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PCSA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PCSA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2$4$6$8$10$12Oct 25Jan 26Apr 26Jul 26PCSA

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Recent analyst actionsNewest first

Of the 19 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
2 Sept 2025HC Wainwright & Co.MaintainsBuy$2.00 → $1.00
30 June 2025HC Wainwright & Co.MaintainsBuy—
5 Dec 2024HC Wainwright & Co.ReiteratesBuy—
3 Oct 2024HC Wainwright & Co.ReiteratesBuy$6.00
20 Aug 2024HC Wainwright & Co.ReiteratesBuy—
19 Aug 2024HC Wainwright & Co.MaintainsBuy—
1 Aug 2024HC Wainwright & Co.ReiteratesBuy—
12 June 2024HC Wainwright & Co.ReiteratesBuy—
13 May 2024HC Wainwright & Co.ReiteratesBuy—
25 Apr 2024HC Wainwright & Co.InitiatesBuy—
6 Mar 2024BenchmarkReiteratesSpeculative Buy—
17 Nov 2023Maxim GroupDowngradeHold—
4 Apr 2023BenchmarkMaintainsSpeculative Buy$9.00 → $4.00
3 Apr 2023OppenheimerMaintainsOutperform$5.00 → $3.00
12 Jan 2023Maxim GroupMaintainsBuy$9.00 → $5.00
19 Apr 2022Maxim GroupInitiatesBuy$9.00
3 Aug 2021OppenheimerInitiatesOutperform—
2 Aug 2021OppenheimerInitiatesOutperform—
28 Oct 2020Craig-HallumInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PCSA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PCSA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 15 Sept 2026, Processa Pharmaceuticals, Inc. returned −60.9% against +16.4% for the S&P 500, dividends included.

PCSA vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Oct 25Jan 26Apr 26Jul 26PCSAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PCSA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Processa Pharmaceuticals, Inc. (PCSA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.9×

Cheaper than 68% of US stocks

Price / sales
—
Price / book
−16.3×

Cheaper than 98% of US stocks

EV / EBITDA
−0.4×

Cheaper than 63% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−464.2%

Higher than 3% of US stocks

Return on assets
−156.8%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Processa Pharmaceuticals, Inc. (PCSA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Processa Pharmaceuticals, Inc. has a market value of $5.3M and an enterprise value of $5.1M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$13.4M.

  • Free cash flow in the twelve months to 30 June 2026: −$13.3M.

  • Processa Pharmaceuticals, Inc. spent $320.0 on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 2.8M.

  • Trailing P/E: 2.9×; forward P/E: −0.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Processa Pharmaceuticals, Inc. employs 12 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Sept 2026

Data provided by Twelve Data

Peers

PCSA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PCSAProcessa Pharmaceuticals, Inc.$5.3M
21
PULMPulmatrix, Inc.$5.3M
43
MLECMoolec Science SA$5.2M
3
LABTLakewood-Amedex Biotherapeutics, Inc.$5.0M
21
HCWBHCW Biologics Inc.$4.9M
63
CELZCreative Medical Technology Holdings, Inc.$5.8M
23
LIMNLiminatus Pharma, Inc.$4.7M
11

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Processa Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PCSA news & analysis

Processa Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewsWire · 1 Sept 2026neutral

Processa Pharmaceuticals announced its participation in two upcoming investor conferences. The company is a clinical-stage pharmaceutical firm developing VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases.

Why it matters — The conference appearances give Processa an opportunity to present its pipeline and engage with the investment community, though the announcement itself contains no new clinical or corporate developments.

Processa Pharmaceuticals, Inc. (PCSA) M&A Call Prepared Remarks Transcript

Seeking Alpha · 29 July 2026neutral

Processa Pharmaceuticals, Inc. held an M&A call, and the prepared remarks transcript was published by Seeking Alpha.

Why it matters — A PCSA watcher would care because the M&A call likely outlines strategic moves such as potential acquisitions or mergers that could affect the company's direction.

Processa buys Vidya Therapeutics, raises $200 million for drug trials

Reuters · 29 July 2026positive

Processa Pharmaceuticals acquired privately held Vidya Therapeutics in an all-stock deal, gaining access to its lead candidate being developed to target diseases involving the immune system.

Why it matters — The acquisition gives Processa a new pipeline asset aimed at immune-system diseases, potentially broadening the company's therapeutic focus beyond its current programs.

PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC.

GlobeNewsWire · 29 July 2026positive

Processa Pharmaceuticals has acquired Vidya Therapeutics, gaining VT-7208, a next-generation BTK inhibitor for immune-mediated diseases. The acquisition includes a concurrent oversubscribed private placement financing of approximately $200 million.

Why it matters — The acquisition adds a potentially best-in-class BTK inhibitor to Processa's pipeline and provides funding through key clinical milestones into the second half of 2029.

FAQ

Frequently asked questions about PCSA stock

Is PCSA stock a buy right now?

Of the 1 analysts covering Processa Pharmaceuticals, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Processa Pharmaceuticals, Inc. 21 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PCSA?

As at 14 Sept 2026, Processa Pharmaceuticals, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).

What is the PCSA stock forecast for 2030?

No analyst covering Processa Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PCSA are extrapolating price history, which says nothing about the business.

How has PCSA stock performed over the past year?

Processa Pharmaceuticals, Inc. returned -60.9% over the 12 months to 15 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Processa Pharmaceuticals, Inc. do?

Processa Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation chemotherapy and other therapies for serious diseases with high unmet medical needs.

What is the latest news on PCSA?

The most recent item we track (GlobeNewsWire, 1 Sept 2026): "Processa Pharmaceuticals to Participate in Upcoming Investor Conferences". Processa Pharmaceuticals announced its participation in two upcoming investor conferences. The company is a clinical-stage pharmaceutical firm developing VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases.

Company

About Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation chemotherapy and other therapies for serious diseases with high unmet medical needs. The company’s current portfolio centers on oncology programs designed to improve the safety and efficacy of existing cancer treatments by modifying how approved drugs are metabolized and distributed while preserving their cancer-killing mechanisms. Its pipeline also includes non-oncology candidates for conditions such as gastroparesis and glomerular disease. Processa Pharmaceuticals uses a regulatory science-driven approach to advance drug candidates that aim to offer better treatment options for patients facing complex medical conditions. Headquartered in Vero Beach, Florida, Processa Pharmaceuticals participates in the broader pharmaceutical innovation market through research, clinical development, and product pipeline advancement.

CEO Mr. George K. Ng Esq., J.D. · 12 employees · United States · https://www.processapharmaceuticals.com